busulfan has been researched along with Thrombocythemia, Essential in 85 studies
Thrombocythemia, Essential: A clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Therapeutic options for patients with polycythemia vera (PV) and essential thrombocythemia (ET) resistant or intolerant to hydroxyurea are limited." | 9.19 | Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. ( Alvarez-Larrán, A; Ancochea, A; Angona, A; Antelo, ML; Bellosillo, B; Besses, C; Burgaleta, C; Cervantes, F; Durán, MA; Ferrer-Marín, F; Gómez, M; Gómez-Casares, MT; Hernández-Boluda, JC; Marcote, B; Martínez-Avilés, L; Martínez-Trillos, A; Mata, MI; Senín, A; Vicente, V; Xicoy, B, 2014) |
| " From 1974 to 1986 we treated 20 symptomatic ET patients with microvascular circulation disturbances including erythromelalgia (N = 18), atypical or typical transient ischemic attacks (N = 6), or acute coronary ischemic syndrome (N = 3) with aspirin and one course of busulfan." | 9.09 | Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia. ( Michiels, JJ, 1999) |
| "Hydroxyurea (HU) has traditionally been the first-line treatment for patients with polycythemia vera (PV) or essential thrombocythemia (ET) at high risk for vascular complications." | 8.90 | Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea. ( Newberry, KJ; Sever, M; Verstovsek, S, 2014) |
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 7.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| "Therapeutic options for patients with polycythemia vera (PV) and essential thrombocythemia (ET) resistant or intolerant to hydroxyurea are limited." | 5.19 | Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. ( Alvarez-Larrán, A; Ancochea, A; Angona, A; Antelo, ML; Bellosillo, B; Besses, C; Burgaleta, C; Cervantes, F; Durán, MA; Ferrer-Marín, F; Gómez, M; Gómez-Casares, MT; Hernández-Boluda, JC; Marcote, B; Martínez-Avilés, L; Martínez-Trillos, A; Mata, MI; Senín, A; Vicente, V; Xicoy, B, 2014) |
| " From 1974 to 1986 we treated 20 symptomatic ET patients with microvascular circulation disturbances including erythromelalgia (N = 18), atypical or typical transient ischemic attacks (N = 6), or acute coronary ischemic syndrome (N = 3) with aspirin and one course of busulfan." | 5.09 | Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia. ( Michiels, JJ, 1999) |
| "We have previously demonstrated that hydroxyurea (HU) reduces the rate of vascular complications in patients with essential thrombocythaemia (ET) at high risk of thrombosis." | 5.09 | Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. ( Barbui, T; Finazzi, G; Rodeghiero, F; Ruggeri, M, 2000) |
| "Hydroxyurea (HU) has traditionally been the first-line treatment for patients with polycythemia vera (PV) or essential thrombocythemia (ET) at high risk for vascular complications." | 4.90 | Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea. ( Newberry, KJ; Sever, M; Verstovsek, S, 2014) |
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 3.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| " Two patients had been treated with uracil mustard: One developed acute myelogenous leukemia 79 months after institution of therapy, and the other patient developed chronic myelomonocytic leukemia 24 months after the start of therapy." | 3.67 | Essential thrombocythemia and leukemic transformation. ( Curtis, JL; Levin, J; Sedlacek, SM; Weintraub, J, 1986) |
| "Controlled studies are needed to confirm the clinical outcome value of twice-daily vs once-daily aspirin dosing and the therapeutic role of pegylated interferons and direct oral anticoagulants." | 2.66 | Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2020) |
| "Treatment with busulfan or interferon-α is usually effective in hydroxyurea failures." | 2.48 | Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. ( Tefferi, A, 2012) |
| "Aspirin (ASS) was the most frequently used drug in 47 of 93 recorded cases (51%)." | 2.39 | Essential thrombocythemia and pregnancy. ( Griesshammer, M; Heimpel, H; Pearson, TC, 1996) |
| "The risk of major thrombosis is higher in ET patients aged more than 60 ys." | 2.39 | Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. ( Barbui, T; Brière, J; Dupuy, E; Finazzi, G; Kiladjian, JJ, 1996) |
| "Risk of thrombosis is higher in JAK2-mutated ET." | 1.51 | Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2019) |
| "This study indicates that in myelofibrosis, NMA regimens result in high engraftment failure rates." | 1.42 | Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis. ( Broers, AE; Janssen, JJ; Raymakers, R; Slot, S; Smits, K; Te Boekhorst, PA; van de Donk, NW; Witte, BI; Zweegman, S, 2015) |
| "Since bone marrow biopsy revealed myelofibrosis, she received anabolic hormone therapy." | 1.35 | [Long-term remission of non-Hodgkin lymphoma secondary to the treatment for essential thrombocythemia]. ( Kubota, Y; Waki, M, 2009) |
| "Hydroxyurea and myelosan were mostly used as cytostatic drugs while erythrocyte mass transfusions and hemoexfusions (phlebotomy)--for life-support." | 1.32 | [Choice of therapy and overall survival in patients with chronic myeloproliferative diseases]. ( Pop, VP; Rukavitsyn, OA; Seriakov, AP, 2004) |
| "The patient who had trisomy 8 at the time of diagnosis underwent myeloid blastic transformation in 35 months." | 1.31 | Leukemic transformation with trisomy 8 in essential thrombocythemia: a report of four cases. ( Hirose, Y; Masaki, Y; Sugai, S, 2002) |
| "Busulfan was given again for 40 days (a total of 80 mg) in another hospital when the platelet count increased to 71." | 1.30 | [Complete remission of essential thrombocythemia after recovery from severe bone marrow aplasia induced by busulfan treatment]. ( Hamaguchi, H; Nagata, K; Yamamoto, K, 1997) |
| "A 91-year-old patient with essential thrombocythemia presented with marked bone marrow suppression induced by long-term administration of busulfan." | 1.29 | [Effect of G-CSF and M-CSF on busulfan-induced marrow failure in a 91-year old patient with essential thrombocythemia]. ( Kubota, K; Kurabayashi, H; Shirakura, T; Take, H; Tamura, K, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 39 (45.88) | 18.7374 |
| 1990's | 22 (25.88) | 18.2507 |
| 2000's | 15 (17.65) | 29.6817 |
| 2010's | 7 (8.24) | 24.3611 |
| 2020's | 2 (2.35) | 2.80 |
| Authors | Studies |
|---|---|
| Tefferi, A | 7 |
| Barbui, T | 6 |
| Renso, R | 1 |
| Aroldi, A | 1 |
| Pioltelli, P | 1 |
| Gambacorti-Passerini, C | 1 |
| Elli, EM | 1 |
| Sever, M | 1 |
| Newberry, KJ | 1 |
| Verstovsek, S | 1 |
| Alvarez-Larrán, A | 1 |
| Martínez-Avilés, L | 1 |
| Hernández-Boluda, JC | 1 |
| Ferrer-Marín, F | 1 |
| Antelo, ML | 1 |
| Burgaleta, C | 1 |
| Mata, MI | 1 |
| Xicoy, B | 1 |
| Martínez-Trillos, A | 1 |
| Gómez-Casares, MT | 1 |
| Durán, MA | 1 |
| Marcote, B | 1 |
| Ancochea, A | 1 |
| Senín, A | 1 |
| Angona, A | 1 |
| Gómez, M | 1 |
| Vicente, V | 1 |
| Cervantes, F | 1 |
| Bellosillo, B | 1 |
| Besses, C | 1 |
| Slot, S | 1 |
| Smits, K | 1 |
| van de Donk, NW | 1 |
| Witte, BI | 1 |
| Raymakers, R | 1 |
| Janssen, JJ | 1 |
| Broers, AE | 1 |
| Te Boekhorst, PA | 1 |
| Zweegman, S | 1 |
| Begna, K | 1 |
| Abdelatif, A | 1 |
| Schwager, S | 1 |
| Hanson, C | 1 |
| Pardanani, A | 1 |
| Radaelli, F | 1 |
| Onida, F | 1 |
| Rossi, FG | 1 |
| Zilioli, VR | 1 |
| Colombi, M | 1 |
| Usardi, P | 1 |
| Calori, R | 1 |
| Zanella, A | 1 |
| Kubota, Y | 1 |
| Waki, M | 1 |
| Sironi, M | 1 |
| Bertola, G | 1 |
| Lodato, A | 1 |
| Spinelli, M | 1 |
| Sciariada, L | 1 |
| Deeg, HJ | 1 |
| Gooley, TA | 1 |
| Flowers, ME | 1 |
| Sale, GE | 1 |
| Slattery, JT | 1 |
| Anasetti, C | 1 |
| Chauncey, TR | 1 |
| Doney, K | 1 |
| Georges, GE | 1 |
| Kiem, HP | 1 |
| Martin, PJ | 1 |
| Petersdorf, EW | 1 |
| Radich, J | 1 |
| Sanders, JE | 1 |
| Sandmaier, BM | 1 |
| Warren, EH | 1 |
| Witherspoon, RP | 1 |
| Storb, R | 1 |
| Appelbaum, FR | 1 |
| EISEN, B | 1 |
| BUTZ, WC | 1 |
| WEBB, AT | 1 |
| MEYER, FL | 1 |
| LONSER, ER | 1 |
| CAMPANALE, RP | 1 |
| BARBIERI, U | 1 |
| ASCARI, E | 1 |
| GOBBI, F | 1 |
| RYDER, RJ | 1 |
| HALL, WJ | 1 |
| OHLER, WG | 1 |
| FRIEDERICI, L | 1 |
| CASTENHOLZ, A | 1 |
| Candoni, A | 1 |
| Tiribelli, M | 1 |
| Fanin, R | 1 |
| Rukavitsyn, OA | 1 |
| Pop, VP | 1 |
| Seriakov, AP | 1 |
| Mizukoshi, T | 1 |
| Fujino, Y | 1 |
| Yasukawa, K | 1 |
| Matumoto, H | 1 |
| Matsumura, S | 1 |
| Nagasaki, T | 1 |
| Ohno, K | 1 |
| Tsujimoto, H | 1 |
| Shimoda, T | 1 |
| Shvidel, L | 1 |
| Sigler, E | 1 |
| Haran, M | 1 |
| Klepfish, A | 1 |
| Duek, A | 1 |
| Berrebi, A | 2 |
| Shtalrid, M | 1 |
| Krug, K | 1 |
| Rohrberg, R | 1 |
| Wessel, H | 1 |
| Zurborn, KH | 1 |
| Bruhn, HD | 1 |
| Feller, A | 1 |
| Sanz Marca, A | 1 |
| Rico Pérez, MT | 1 |
| Aboín Massieu, FJ | 1 |
| Rebollar Mesa, JL | 1 |
| Grebe, G | 1 |
| Alvo, M | 1 |
| Lira, P | 1 |
| Barria, C | 1 |
| Mezzano, D | 1 |
| Monsalve, V | 1 |
| Linker, H | 1 |
| Lindner, HJ | 1 |
| Reuter, H | 1 |
| Gross, R | 1 |
| Take, H | 1 |
| Tamura, K | 1 |
| Kurabayashi, H | 1 |
| Kubota, K | 1 |
| Shirakura, T | 1 |
| Bieniaszewska, M | 1 |
| Hellmann, A | 1 |
| Kabata, J | 1 |
| Rasze-Ja-Specht, A | 1 |
| van Genderen, PJ | 1 |
| Michiels, JJ | 3 |
| Arnar, DO | 1 |
| Pétursson, MK | 1 |
| Jónmundsson, E | 1 |
| Björnsdóttir, J | 1 |
| Tura, S | 1 |
| Meisel, S | 1 |
| Shpilberg, O | 1 |
| Ramot, B | 1 |
| Ben-Bassat, I | 1 |
| Grande, M | 1 |
| Nand, S | 1 |
| Stock, W | 1 |
| Godwin, J | 1 |
| Fisher, SG | 1 |
| Carulli, G | 1 |
| Minnucci, S | 1 |
| Gianfaldoni, ML | 1 |
| Angiolini, C | 1 |
| Azzarà, A | 1 |
| Ambrogi, F | 1 |
| Griesshammer, M | 1 |
| Heimpel, H | 1 |
| Pearson, TC | 2 |
| Finazzi, G | 3 |
| Dupuy, E | 1 |
| Kiladjian, JJ | 1 |
| Brière, J | 1 |
| Fernández, MC | 1 |
| Gardelegui, I | 1 |
| Capote, FJ | 1 |
| Gil, JL | 1 |
| Muñoz, JA | 1 |
| Yamamoto, K | 1 |
| Nagata, K | 1 |
| Hamaguchi, H | 1 |
| Randi, ML | 6 |
| Barbone, E | 1 |
| Zerbinati, P | 1 |
| Soini, B | 1 |
| Rossi, C | 3 |
| Girolami, A | 6 |
| Brodsky, I | 1 |
| Fabris, F | 5 |
| Menapace, L | 1 |
| Ruggeri, M | 1 |
| Rodeghiero, F | 2 |
| Jantunen, R | 1 |
| Juvonen, E | 1 |
| Ikkala, E | 1 |
| Oksanen, K | 1 |
| Anttila, P | 1 |
| Ruutu, T | 1 |
| Wright, CA | 1 |
| Hirose, Y | 1 |
| Masaki, Y | 1 |
| Sugai, S | 1 |
| Selroos, O | 1 |
| van Assendelft, A | 1 |
| Singh, AK | 2 |
| Wetherley-Mein, G | 2 |
| Droszcz, W | 1 |
| Mdzewski, B | 1 |
| Wrońska, J | 1 |
| Porembińska, H | 1 |
| Jedrzejewski, R | 1 |
| Bogacka-Zatorska, H | 1 |
| Leifer, W | 1 |
| Leifer, G | 1 |
| Lennert, K | 1 |
| Nagai, K | 1 |
| Schwarze, EW | 1 |
| Jeri, A | 1 |
| Horna, E | 1 |
| Rojas, M | 1 |
| Grossi, A | 1 |
| Vannucchi, AM | 1 |
| Longo, G | 1 |
| Rafanelli, D | 1 |
| Rossi Ferrini, P | 1 |
| Scheffer, MG | 1 |
| Simoons, ML | 1 |
| Roelandt, JR | 1 |
| Cortelazzo, S | 1 |
| Viero, P | 1 |
| D'Emilio, A | 1 |
| Benassi, G | 1 |
| Ricci, P | 1 |
| Calbucci, F | 1 |
| Cacciatore, FM | 1 |
| D'Alessandro, R | 1 |
| Knottenbelt, E | 1 |
| Hallett, J | 1 |
| Jacobs, P | 1 |
| Sedlacek, SM | 1 |
| Curtis, JL | 1 |
| Weintraub, J | 1 |
| Levin, J | 1 |
| Pozzato, G | 1 |
| Terpin, MM | 1 |
| Rinaldi, C | 1 |
| Frezza, M | 1 |
| Krupsky, M | 1 |
| Van de Pette, JE | 1 |
| Prochazka, AV | 1 |
| Dickson, ER | 1 |
| Stathakis, NE | 1 |
| Papayannis, AG | 1 |
| Arapakis, G | 1 |
| Gardikas, C | 1 |
| Jamshidi, K | 1 |
| Ansari, A | 1 |
| Windschitl, HE | 1 |
| Swaim, WR | 1 |
| Solhaug, JH | 1 |
| Martinez, J | 1 |
| Shapiro, SS | 1 |
| Holburn, RR | 1 |
| Wiik, AS | 1 |
| Paulson, OB | 1 |
| Sorensen, CM | 1 |
| Visfeldt, J | 1 |
| Williams, DW | 1 |
| Brandt, L | 1 |
| Torre-Lopez, E | 1 |
| Sanchez-Medal, L | 1 |
| McNutt, DR | 1 |
| Fudenberg, HH | 1 |
| Silverstein, MN | 1 |
| Ravich, RB | 1 |
| Gunz, FW | 1 |
| Thompson, IL | 1 |
| Reed, CS | 1 |
| Prankerd, TA | 1 |
| Frinovskaia, IV | 1 |
| Epstein, IS | 1 |
12 reviews available for busulfan and Thrombocythemia, Essential
| Article | Year |
|---|---|
Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.
Topics: Busulfan; Female; Humans; Janus Kinase 2; Leukemia, Myeloid, Acute; Leukocytosis; Male; Microcircula | 2023 |
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
Topics: Age Factors; Aspirin; Busulfan; Calreticulin; Disease-Free Survival; Humans; Interferon-alpha; Janus | 2020 |
Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.
Topics: Antineoplastic Agents; Busulfan; Disease Management; Drug Resistance; Histone Deacetylase Inhibitors | 2014 |
Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Topics: Acute Disease; Age Factors; Alkylating Agents; Anticoagulants; Aspirin; Busulfan; Disease Management | 2012 |
Plasma cell leukemia occurring in a patient with thrombocythemia treated with hydroxyurea and busulphan.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Membe | 2004 |
Primary thrombocythemia: diagnosis, clinical manifestations and management.
Topics: Adolescent; Adult; Aged; Busulfan; Child; Diagnosis, Differential; Female; Hemorrhage; Humans; Hydro | 1993 |
The management of elderly patients with myeloproliferative disorders.
Topics: Adult; Age Factors; Aged; Bone Marrow Transplantation; Busulfan; Chronic Disease; Humans; Hydroxyure | 1993 |
Essential thrombocythemia and pregnancy.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Aspirin; Busulfan; Combined Modality Therapy; Di | 1996 |
Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
Topics: Adult; Aged; Alkylating Agents; Anemia, Megaloblastic; Arrhythmias, Cardiac; Bone Marrow Diseases; B | 1996 |
A single institutional experience with 43 pregnancies in essential thrombocythemia.
Topics: Abortion, Induced; Abortion, Spontaneous; Abruptio Placentae; Adult; Anticoagulants; Aspirin; Busulf | 2001 |
Patho-anatomical features of the bone marrow.
Topics: Bone Marrow; Busulfan; Diagnosis, Differential; Erythropoiesis; Granulocytes; Humans; Leukemia, Myel | 1975 |
[Essential thrombocythemia: conventional therapy].
Topics: Adult; Antineoplastic Agents; Busulfan; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea; Immunolo | 1991 |
6 trials available for busulfan and Thrombocythemia, Essential
| Article | Year |
|---|---|
Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
Topics: Aged; Aged, 80 and over; Alkylating Agents; Blood Cell Count; Busulfan; Comorbidity; Disease Progres | 2014 |
Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; C | 2003 |
Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Busulfan; Female; Humans; Male; Middle A | 2007 |
Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Busulfan; Coronary Disease; Dise | 1999 |
Aspirin seems as effective as myelosuppressive agents in the prevention of rethrombosis in essential thrombocythemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Busulfan; Disease-Free Survival; Female; Hemorr | 1999 |
Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Busul | 2000 |
67 other studies available for busulfan and Thrombocythemia, Essential
| Article | Year |
|---|---|
Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Busulfan; Drug Resistance; Female; Humans; Hyd | 2018 |
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Topics: Adult; Aspirin; Bone Marrow; Busulfan; Disease Management; Disease Progression; Hemorrhage; Humans; | 2019 |
Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Calreticulin; Com | 2015 |
Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Busulfan; Female; Humans; Male; M | 2016 |
Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alkylating Agents; Busulfan; Drug Therapy, Combination; | 2008 |
[Long-term remission of non-Hodgkin lymphoma secondary to the treatment for essential thrombocythemia].
Topics: Alkylating Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Co | 2009 |
Transition of essential thrombocythemia to megakaryoblastic leukemia after long-term therapy with sequential busulfan, pipobroman and hydroxyurea.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Humans; Hydroxyurea; Leukemia | 2003 |
Primary hemorrhagic thrombocythemia treated with Myeleran.
Topics: Blood Platelets; Busulfan; Hemorrhagic Disorders; Humans; Thrombocythemia, Essential | 1962 |
Hemorrhagic thrombocythemia. Response to busulfan.
Topics: Blood Platelets; Busulfan; Female; Hemorrhage; Humans; Postpartum Hemorrhage; Postpartum Period; Thr | 1963 |
PRIMARY THROMBOCYTHEMIA: A SURGICAL PARADOX. REPORT OF A CASE.
Topics: Blood Platelets; Busulfan; Cell Count; Drug Therapy; Hemorrhagic Disorders; Humans; Hyperplasia; Meg | 1964 |
[HEMORRHAGIC THROMBOCYTHEMIA AND THE "MYELOPROLIFERATIVE SYNDROME"].
Topics: Anemia; Anemia, Hypochromic; Blood Platelets; Busulfan; Gastrointestinal Hemorrhage; Hemorrhage; Hem | 1964 |
[HEMORRHAGIC THROMBOCYTHEMIA].
Topics: Blood Platelet Disorders; Blood Platelets; Busulfan; Hemorrhagic Disorders; Humans; Phospholipids; R | 1964 |
HAEMORRHAGIC THROMBOCYTHAEMIA.
Topics: Blood Coagulation Tests; Blood Platelet Disorders; Blood Platelets; Busulfan; Drug Therapy; Humans; | 1965 |
HEMORRHAGIC THROMBOCYTHEMIA: REPORT OF A CASE.
Topics: Bone Marrow Examination; Busulfan; Chromosomes; Diagnosis; Drug Therapy; Humans; Purpura; Thrombocyt | 1965 |
[CONTRIBUTION TO THE CLINICAL PICTURE OF HEMORRHAGIC THROMBOCYTHEMIA].
Topics: Busulfan; Hemorrhagic Disorders; Leukocyte Disorders; Leukocytosis; Thrombocythemia, Essential | 1965 |
[Choice of therapy and overall survival in patients with chronic myeloproliferative diseases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; | 2004 |
Essential thrombocythemia in a dog.
Topics: Animals; Busulfan; Dog Diseases; Dogs; Drug Therapy, Combination; Male; Prednisolone; Thrombocythemi | 2006 |
[Megakaryocytic pseudomyelosis with severe thrombocytosis].
Topics: Aged; Alkaline Phosphatase; Alpha-Globulins; Busulfan; Female; Humans; Leucyl Aminopeptidase; Liver; | 1981 |
[Therapy of blast crises in megakaryocytic myelosis].
Topics: Busulfan; Female; Humans; Middle Aged; Neoplastic Stem Cells; Stem Cells; Thrombocythemia, Essential | 1984 |
[Essential thrombocythemia. Apropos of 3 cases].
Topics: Adult; Aged; Anticoagulants; Busulfan; Female; Humans; Male; Thrombocythemia, Essential | 1983 |
[Essential thrombocythemia: clinical and laboratory study of 6 cases].
Topics: Aged; Bone Marrow; Busulfan; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Count | 1983 |
[Long-term treatment of thrombocytosis and thrombocythemia].
Topics: Busulfan; Humans; Myeloproliferative Disorders; Pyrimethamine; Thrombocythemia, Essential; Thrombocy | 1980 |
[Effect of G-CSF and M-CSF on busulfan-induced marrow failure in a 91-year old patient with essential thrombocythemia].
Topics: Aged; Aged, 80 and over; Bone Marrow; Busulfan; Female; Granulocyte Colony-Stimulating Factor; Human | 1993 |
[Essential thrombocythemia--clinical course from personal material].
Topics: Adult; Aged; Aged, 80 and over; Busulfan; Female; Humans; Hydroxyurea; Interferon-alpha; Male; Middl | 1994 |
Renovascular hypertension and coronary heart disease complicating essential thrombocythemia.
Topics: Adult; Angioplasty, Balloon; Busulfan; Coronary Disease; Humans; Hypertension, Renovascular; Male; R | 1993 |
Essential thrombocythemia: a relative benign long-term course.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Busulfan; Female; Follow-Up Studies; Hemoglobins; Humans | 1993 |
Central nervous system granulocytic sarcoma in a patient with essential thrombocythemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blast Crisi | 1996 |
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Topics: Acute Disease; Anemia, Refractory, with Excess of Blasts; Busulfan; Cell Transformation, Neoplastic; | 1996 |
Interactions between platelets and neutrophils in essential thrombocythaemia. Effects on neutrophil chemiluminescence and superoxide anion generation.
Topics: Adult; Aged; Blood Platelets; Busulfan; Female; Humans; Luminescent Measurements; Male; Middle Aged; | 1995 |
[Acute myeloid leukemia developing in the course of essential thrombocythemia].
Topics: Alkylating Agents; Busulfan; Cerebral Hemorrhage; Disease Progression; Fatal Outcome; Gingival Hemor | 1996 |
[Complete remission of essential thrombocythemia after recovery from severe bone marrow aplasia induced by busulfan treatment].
Topics: Anemia, Aplastic; Busulfan; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Humans; M | 1997 |
Essential thrombocythemia following polycythemia vera: an unusual sequence.
Topics: Aged; Aged, 80 and over; Alkylating Agents; Busulfan; Hematocrit; Humans; Leukocyte Count; Male; Pho | 1996 |
Busulfan versus hydroxyurea in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET)
Topics: Antineoplastic Agents; Busulfan; Humans; Hydroxyurea; Immunosuppressive Agents; Polycythemia Vera; R | 1998 |
Is hydroxyurea leukemogenic in essential thrombocythemia?
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Bone Marrow; Busulfan; Chromosome Aberrations; Chr | 1998 |
Leukemia and myelodysplasia in patients with essential thrombocythemia treated with cytotoxic agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Busulfan; Female; Follow-Up Studies; Humans; | 1999 |
Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 patients.
Topics: Acute Disease; Adult; Age Factors; Arteriosclerosis; Aspirin; Busulfan; Cohort Studies; Disease-Free | 2000 |
Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Busulfan; Fatal Outcome; Female; Humans; Hydro | 2000 |
The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia.
Topics: Adult; Aged; Aged, 80 and over; Arterial Occlusive Diseases; Blood Platelets; Busulfan; Female; Huma | 2001 |
Second malignancies in patients with essential thrombocythaemia.
Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Female; Follow-Up Studies; Humans; Hydroxyurea; Male; | 2002 |
Leukemic transformation with trisomy 8 in essential thrombocythemia: a report of four cases.
Topics: Adult; Aged; Aged, 80 and over; Bone Marrow; Busulfan; Cell Transformation, Neoplastic; Chromosomes, | 2002 |
Thrombocythaemia and multiple myeloma. A report on two cases.
Topics: Aged; Blood Cell Count; Blood Platelets; Bone Marrow Cells; Busulfan; Female; Follow-Up Studies; Hum | 1977 |
Microvascular occlusive lesions in primary thrombocythaemia.
Topics: Adult; Aged; Busulfan; Capillaries; Diagnosis, Differential; Female; Gangrene; Humans; Ischemia; Mal | 1977 |
[Case of megakaryocyte leukemia with an unusual course].
Topics: Adult; Busulfan; Female; Humans; Liver; Remission, Spontaneous; Thrombocythemia, Essential | 1978 |
Priapsim caused by primary thrombocythemia.
Topics: Adult; Blood Cell Count; Bone Marrow; Busulfan; Humans; Male; Plateletpheresis; Priapism; Thrombocyt | 1979 |
[Essential thrombocytosis. Presentation of one case (author's transl)].
Topics: Adult; Aspirin; Busulfan; Humans; Male; Thrombocythemia, Essential | 1975 |
Thrombocythemia and coronary artery disease.
Topics: Adult; Aged; Aspirin; Busulfan; Coronary Disease; Female; Humans; Male; Middle Aged; Polycythemia Ve | 1991 |
Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Busulfan; Cohort Studies; Female; Follow-Up Studies; Hem | 1990 |
Slowly progressive ischemic stroke as first manifestation of essential thrombocythemia.
Topics: Adult; Arterial Occlusive Diseases; Brain Ischemia; Busulfan; Cerebral Arterial Diseases; Humans; Ma | 1989 |
8;21 translocation in myelodysplasia secondary to essential thrombocythemia.
Topics: Aged; Busulfan; Cell Transformation, Neoplastic; Cytogenetics; Female; Humans; Karyotyping; Leukemia | 1989 |
Essential thrombocythemia and leukemic transformation.
Topics: Adult; Aged; Bone Marrow; Busulfan; Cell Transformation, Neoplastic; Humans; Leukemia, Myeloid; Leuk | 1986 |
[Clinical case. Primary thrombocythemia].
Topics: Adult; Busulfan; Diagnosis, Differential; Female; Humans; Mitobronitol; Thrombocythemia, Essential | 1987 |
[Essential thrombocythemia].
Topics: Adult; Aged; Aged, 80 and over; Bone Marrow; Busulfan; Humans; Middle Aged; Platelet Aggregation; Pr | 1987 |
Primary thrombocythaemia treated with busulphan.
Topics: Adult; Aged; Blood Cell Count; Bone Marrow; Busulfan; Female; Humans; Male; Middle Aged; Philadelphi | 1986 |
Platelet dysfunction in essential thrombocythaemia.
Topics: Adenosine Diphosphate; Aged; Blood Cell Count; Blood Coagulation; Blood Platelets; Busulfan; Collage | 1974 |
Primary thrombocythemia.
Topics: Adult; Aged; Blood Coagulation Tests; Bone Marrow Examination; Busulfan; Follow-Up Studies; Gastroin | 1973 |
Thrombocytosis. A source of increased bleeding tendency.
Topics: Aged; Blood Cell Count; Blood Platelets; Busulfan; Carcinoma; Colon, Sigmoid; Colonic Neoplasms; Div | 1973 |
Metabolism of human prothrombin and fibrinogen in patients with thrombocytosis secondary to myeloproliferative states.
Topics: Adolescent; Adult; Aged; Alkaline Phosphatase; Blood Cell Count; Blood Coagulation Factors; Blood Co | 1973 |
A study of 51 Cr-labelled platelets and the chromosomal pattern in a case of primary haemorrhagic thrombocythaemia.
Topics: Aged; Blood Platelets; Blood Transfusion; Bone Marrow Cells; Busulfan; Cell Survival; Chromium Isoto | 1971 |
Busulfan in early pregnancy.
Topics: Adult; Busulfan; Female; Humans; Leukemia, Myeloid; Pregnancy; Pregnancy Complications, Hematologic; | 1966 |
Studies on the phagocytic activity of neutrophilic leukocytes.
Topics: Adult; Age Factors; Aged; Alkaline Phosphatase; Anemia, Macrocytic; Animals; Biopsy; Bone Marrow Dis | 1967 |
[Primary hemorrhagic thrombocythemia. 3 cases].
Topics: Aged; Anemia, Aplastic; Bone Marrow Examination; Busulfan; Female; Humans; Leukemia, Myeloid; Male; | 1971 |
Disseminated scotochromogen infection and unusual myeloproliferative disorder. Report of a case and review of the literature.
Topics: Adolescent; Adult; Aged; Autopsy; Busulfan; Child; Child, Preschool; Chlorambucil; Female; Humans; L | 1971 |
Primary or hemorrhagic thrombocythemia.
Topics: Adult; Anemia, Hypochromic; Busulfan; Female; Gastrointestinal Hemorrhage; Humans; Leukocytosis; Mal | 1968 |
The dangers of surgery in uncontrolled haemorrhagic thrombocythaemia.
Topics: Aged; Blood Cell Count; Blood Platelets; Busulfan; Hemorrhage; Humans; Male; Middle Aged; Peptic Ulc | 1970 |
The management of platelet disorders.
Topics: Blood Platelets; Blood Transfusion; Busulfan; Glucocorticoids; Humans; Immunosuppressive Agents; Pho | 1968 |
[Some questions on the problem of thrombocythemia].
Topics: Busulfan; Female; Gold Isotopes; Humans; Male; Phosphorus Isotopes; Radionuclide Imaging; Thrombocyt | 1968 |
The treatment of Polycythemia vera and thrombocythemia with myleran (busulphan).
Topics: Aged; Anemia; Busulfan; Female; Humans; Male; Phosphorus Isotopes; Polycythemia Vera; Thrombocythemi | 1965 |